DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 20-449/S-036

Sanofi-Aventis
300 Somerset Corporation Blvd
Bridgewater, NJ 08807-0977

Attention: Jay Kraker
Specialist
U.S. Regulatory Affairs Marketed Products

Dear Mr. Kraker:

Please refer to your supplemental new drug application dated December 21, 2005, received December 22, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Taxotere® (docetaxel) for Injection Concentrate, 20 mg and 80 mg.

This "Changes Being Effected" supplemental new drug application provides for changes to the package insert Black Box Warning and WARNINGS, Hypersensitivity Reactions subsection to include a new warning for severe hypersensitivity reactions and to add four new sections to the ADVERSE REACTIONS, Post-marketing Experiences subsection.

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on December 21, 2005.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Ann Staten, Regulatory Project Manager, at (301) 796-1468.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D.
Acting Director
Division of Drug Oncology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Ann Farrell
6/7/2006 10:23:49 AM
Farrell for Justice